Eli Lilly and Company $LLY Holdings Decreased by Altus Wealth Group LLC

Altus Wealth Group LLC reduced its stake in shares of Eli Lilly and Company (NYSE:LLY) by 16.5% during the second quarter, Holdings Channel.com reports. The firm owned 294 shares of the company’s stock after selling 58 shares during the period. Altus Wealth Group LLC’s holdings in Eli Lilly and Company were worth $229,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Precedent Wealth Partners LLC grew its holdings in Eli Lilly and Company by 15.3% during the second quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock worth $229,000 after acquiring an additional 39 shares during the period. Capital Advisors Inc. OK grew its holdings in Eli Lilly and Company by 6.8% during the second quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock worth $5,260,000 after acquiring an additional 429 shares during the period. Family CFO Inc acquired a new position in Eli Lilly and Company during the second quarter worth about $54,000. Duquesne Family Office LLC grew its holdings in Eli Lilly and Company by 52.5% during the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock worth $78,321,000 after acquiring an additional 32,640 shares during the period. Finally, Corient IA LLC acquired a new position in Eli Lilly and Company during the first quarter worth about $570,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Down 1.9%

Shares of LLY opened at $803.53 on Monday. The business’s 50-day moving average price is $753.09 and its 200 day moving average price is $765.70. The stock has a market capitalization of $760.51 billion, a P/E ratio of 52.52, a P/E/G ratio of 1.15 and a beta of 0.47. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $935.63. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter in the previous year, the business posted $3.92 EPS. The business’s revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, Director Gabrielle Sulzberger bought 117 shares of the stock in a transaction on Tuesday, August 12th. The shares were bought at an average price of $641.18 per share, with a total value of $75,018.06. Following the purchase, the director directly owned 2,703 shares in the company, valued at $1,733,109.54. The trade was a 4.52% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director J Erik Fyrwald bought 1,565 shares of the stock in a transaction on Tuesday, August 12th. The shares were acquired at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the purchase, the director owned 74,578 shares in the company, valued at approximately $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 4,514 shares of company stock worth $2,894,841. Company insiders own 0.14% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on LLY. Leerink Partners reaffirmed a “market perform” rating and set a $715.00 target price on shares of Eli Lilly and Company in a report on Thursday, August 7th. HSBC lifted their target price on Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. Daiwa America cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 17th. Leerink Partnrs cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 7th. Finally, Deutsche Bank Aktiengesellschaft dropped their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research note on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $939.12.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.